# Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

> **NCT00087763** · PHASE2 · COMPLETED · sponsor: **Eyetech Pharmaceuticals** · enrollment: 135 (—)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Macugen ™ (pegaptanib sodium injection)

## Key facts

- **NCT ID:** NCT00087763
- **Lead sponsor:** Eyetech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 135 (—)
- **Last updated:** 2006-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087763, "Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00087763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*